Karen E. Malone
Research Subjects
Karen E. Malone has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Ash Jayagopal
Opus Genetics, Durham, North Carolina, USA
3 shared publicationsMathijs Gaastra
GeneScape, Leiden, the Netherlands
3 shared publicationsMatthijs Leenders
GeneScape, Leiden, the Netherlands
3 shared publicationsGeorge Magrath
Opus Genetics, Durham, North Carolina, USA
2 shared publicationsSarah Tuller
Opus Genetics, Durham, North Carolina, USA
2 shared publicationsAndre Schmidt
D-PharmXchange
1 shared publication
Latest Publications
- Open Access
- 16 September 2026
- Published by BMJ in BMJ Connections Clinical Genetics and Genomics
- Vol. 3 (1) , e000086
Review and meta-analysis of BEST1 retinopathy: global prevalence and mutational landscape
PURPOSEBEST1-associated inherited retinal disease constitutes one of the largest inherited retinal disease patient populations across the world. Innovative therapies are currently in development to address this significant unmet need. To better understand the scale of unmet need, and the distribution of phenotypes and genotypes, we conducted a meta-analysis of BEST1 patients reported in the literature to provide up-to-date patient number estimates. We used the GeneScape IRD Patient Atlas , an expertly curated database of ~73K retinal disease patients undergoing extensive genetic testing, in combination with a dedicated literature search to estimate the proportion of inherited retinal dystrophy (IRD) patients attributed to BEST1 using fixed effects weighting. This was also translated to patient number estimates for each country. Further extrapolation of patient subtypes was estimated based on cohorts of BEST1 patients reporting phenotypes and genotypes. In addition, a summary of contributing variants is reported by region. Across all studied regions, BEST1 retinopathy affects an estimated 24,000 patients, with prevalence varying nearly tenfold between regions: from 1 in 38,000 in Germany to 1 in 363,000 in Japan, though estimates for China carry considerable uncertainty. In western countries, biallelic patients are expected to contribute nearly 20% of the total BEST1 population, whereas one third of patients in East Asia are anticipated to be biallelic. While patients are reported across the world, their prevalence and composition vary across geographies. In the literature, biallelic patients are less often reported explicitly as autosomal recessive Best patients in the USA as compared with Europe. Variant diversity in BEST1 patients is reflected in regional reports and drives phenotypic distribution.
- 16 September 2026
- Published by BMJ in BMJ Connections Clinical Genetics and Genomics
- Vol. 3 (1) , e000086
Open AccessReview and meta-analysis of BEST1 retinopathy: global prevalence and mutational landscape
PURPOSEBEST1-associated inherited retinal disease constitutes one of the largest inherited retinal disease patient populations across the world. Innovative therapies are currently in development to address this significant unmet need. To better understand the scale of unmet need, and the distribution of phenotypes and genotypes, we conducted a meta-analysis of BEST1 patients reported in the literature to provide up-to-date patient number estimates. We used the GeneScape IRD Patient Atlas , an expertly curated database of ~73K retinal disease patients undergoing extensive genetic testing, in combination with a dedicated literature search to estimate the proportion of inherited retinal dystrophy (IRD) patients attributed to BEST1 using fixed effects weighting. This was also translated to patient number estimates for each country. Further extrapolation of patient subtypes was estimated based on cohorts of BEST1 patients reporting phenotypes and genotypes. In addition, a summary of contributing variants is reported by region. Across all studied regions, BEST1 retinopathy affects an estimated 24,000 patients, with prevalence varying nearly tenfold between regions: from 1 in 38,000 in Germany to 1 in 363,000 in Japan, though estimates for China carry considerable uncertainty. In western countries, biallelic patients are expected to contribute nearly 20% of the total BEST1 population, whereas one third of patients in East Asia are anticipated to be biallelic. While patients are reported across the world, their prevalence and composition vary across geographies. In the literature, biallelic patients are less often reported explicitly as autosomal recessive Best patients in the USA as compared with Europe. Variant diversity in BEST1 patients is reflected in regional reports and drives phenotypic distribution.
- Open Access
Review and Meta-Analysis of BEST1 Retinopathy: Global Prevalence and Mutational Landscape
PURPOSE: BEST1-associated inherited retinal disease constitutes one of the largest inherited retinal disease patient populations across the world. Innovative therapies are currently in development to address this significant unmet need. To better understand the scale of unmet need, and the distribution of phenotypes and genotypes, we conducted a meta-analysis of BEST1 patients reported in the literature to provide up-to-date patient number estimates. METHODS: We utilized the GeneScape IRD Patient Atlas, an expertly curated database of ~73K retinal disease patients undergoing extensive genetic testing, in combination with a dedicated literature search to estimate the proportion of IRD patients attributed to BEST1 using fixed effects weighting. This was also translated to patient number estimates for each country. Further extrapolation of patient subtypes was estimated based on cohorts of BEST1 patients reporting phenotypes and genotypes. In addition, a summary of contributing variants is reported by region. RESULTS: Across regions BEST1 retinopathy patients are estimated to occur from 1 in 38K (in Germany) to 1 in 363K in Japan. In the western countries, bi-allelic patients are expected to contribute nearly 20% of the total BEST1 population, whereas one third of patients in East Asia are anticipated to be bi-allelic. CONCLUSIONS: While patients are reported across the world, their prevalence and composition vary across geographies. In the literature bi-allelic patients are less often reported explicitly as ARB patients in the United States as compared to Europe. Variant diversity is reflected in regional reports and drives phenotypic distribution.
Open AccessReview and Meta-Analysis of BEST1 Retinopathy: Global Prevalence and Mutational Landscape
PURPOSE: BEST1-associated inherited retinal disease constitutes one of the largest inherited retinal disease patient populations across the world. Innovative therapies are currently in development to address this significant unmet need. To better understand the scale of unmet need, and the distribution of phenotypes and genotypes, we conducted a meta-analysis of BEST1 patients reported in the literature to provide up-to-date patient number estimates. METHODS: We utilized the GeneScape IRD Patient Atlas, an expertly curated database of ~73K retinal disease patients undergoing extensive genetic testing, in combination with a dedicated literature search to estimate the proportion of IRD patients attributed to BEST1 using fixed effects weighting. This was also translated to patient number estimates for each country. Further extrapolation of patient subtypes was estimated based on cohorts of BEST1 patients reporting phenotypes and genotypes. In addition, a summary of contributing variants is reported by region. RESULTS: Across regions BEST1 retinopathy patients are estimated to occur from 1 in 38K (in Germany) to 1 in 363K in Japan. In the western countries, bi-allelic patients are expected to contribute nearly 20% of the total BEST1 population, whereas one third of patients in East Asia are anticipated to be bi-allelic. CONCLUSIONS: While patients are reported across the world, their prevalence and composition vary across geographies. In the literature bi-allelic patients are less often reported explicitly as ARB patients in the United States as compared to Europe. Variant diversity is reflected in regional reports and drives phenotypic distribution.
- Open Access
- 11 July 2025
- Published by ScienceOpen
The Business Case for Drug Repurposing in Cri du Chat Syndrome Patients
Cri du Chat syndrome (CdCS) is a rare genetic disorder caused by spontaneous deletion on the short arm of chromosome 5 (5p-), resulting in developmental delays, intellectual disability, and lifelong unmet medical needs. Despite being well recognized, there are no dedicated therapies that directly address the core symptoms of CdCS, leaving families with only supportive care and limited treatment options. To help close this gap, we collaborated with the Cri du Chat Research Foundation to identify actionable targets. We systematically analyzed and ranked gene targets/pathways with high indication of haploinsufficiency central to CdCS neurological dysfunction implicated in multiple clinical symptoms. Cross-referencing with druggability databases revealed a strong opportunity to repurpose approved drugs. Additional feasibility and market research, including Freedom-to-Operate, indicate we can offer a potentially faster, cost-effective, and lower-risk path to bring meaningful treatment options to CdCS patients. Our target pathway and candidate drugs currently remain undisclosed to facilitate an effective IP strategy. Drug repurposing aligns with our commitment to advance equitable drug development for underserved patient populations. By leveraging compounds with established safety profiles and streamlined regulatory pathways, we aim to reduce time and cost to reach clinical proof-of-concept. The commercial viability is strengthened by opportunities to secure medical use patents, orphan drug incentives, patient registries, and an engaged patient community — ensuring faster access to novel interventions and a sustainable path to market. This CdCS program shows how targeted, data-driven strategies and close patient partnerships can unlock transformative therapies for conditions long overlooked by conventional pipelines.
- 11 July 2025
- Published by ScienceOpen
Open AccessThe Business Case for Drug Repurposing in Cri du Chat Syndrome Patients
Cri du Chat syndrome (CdCS) is a rare genetic disorder caused by spontaneous deletion on the short arm of chromosome 5 (5p-), resulting in developmental delays, intellectual disability, and lifelong unmet medical needs. Despite being well recognized, there are no dedicated therapies that directly address the core symptoms of CdCS, leaving families with only supportive care and limited treatment options. To help close this gap, we collaborated with the Cri du Chat Research Foundation to identify actionable targets. We systematically analyzed and ranked gene targets/pathways with high indication of haploinsufficiency central to CdCS neurological dysfunction implicated in multiple clinical symptoms. Cross-referencing with druggability databases revealed a strong opportunity to repurpose approved drugs. Additional feasibility and market research, including Freedom-to-Operate, indicate we can offer a potentially faster, cost-effective, and lower-risk path to bring meaningful treatment options to CdCS patients. Our target pathway and candidate drugs currently remain undisclosed to facilitate an effective IP strategy. Drug repurposing aligns with our commitment to advance equitable drug development for underserved patient populations. By leveraging compounds with established safety profiles and streamlined regulatory pathways, we aim to reduce time and cost to reach clinical proof-of-concept. The commercial viability is strengthened by opportunities to secure medical use patents, orphan drug incentives, patient registries, and an engaged patient community — ensuring faster access to novel interventions and a sustainable path to market. This CdCS program shows how targeted, data-driven strategies and close patient partnerships can unlock transformative therapies for conditions long overlooked by conventional pipelines.
- Open Access
- 23 April 2025
- Published by Elsevier in Genetics in Medicine Open
- Vol. 3, 103431
Estimation of PEX1-mediated Zellweger spectrum disorder births and population prevalence by population genetics modeling
- 23 April 2025
- Published by Elsevier in Genetics in Medicine Open
- Vol. 3, 103431
Open AccessEstimation of PEX1-mediated Zellweger spectrum disorder births and population prevalence by population genetics modeling
- 14 September 2024
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 268, 340-347
Prevalence Estimates and Genetic Diversity for Autosomal Dominant Retinitis Pigmentosa Due to RHO, c.68C>A (p.P23H) Variant
- 14 September 2024
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 268, 340-347
Prevalence Estimates and Genetic Diversity for Autosomal Dominant Retinitis Pigmentosa Due to RHO, c.68C>A (p.P23H) Variant
- Open Access
- 2 September 2024
- Published by Springer Nature in Research Square
The emerging face of FOXG1 Syndrome: a rare, genetically defined neurodevelopmental disorder coming of age in the genomics era.
Background and Objectives FOXG1 Syndrome was first identified in 2005 and has been closely associated with Rett Syndrome. However, with access to genetic testing an increasing number of patients have been identified that do not fulfill Rett Syndrome clinical criteria. Utilizing genetic surveys of large, severe neurodevelopmental disease (NDD) cohorts, we provide the first prevalence estimates of FOXG1 Syndrome independent of Rett Syndrome clinical criteria. Methods We performed a systematic review and meta-analysis of studies conducting extensive genetic testing on cohorts of severe neurodevelopmental patients within the last ten years. Fourteen studies were included, after exclusion of outliers biased for FOXG1 patients, providing analysis of over 36,000 severe neurodevelopmental disease pediatric patients in total. Results FOXG1 patients accounted for 0.20% [95% CI: 0.15–0.25%] of severe NDD pediatric patients. MECP2 and CDKL5 patients accounted for 0.54% [95% CI: 0.47–0.62%] and 0.35% [95% CI: 0.29–0.41%], respectively. This results in an estimated prevalence of 0.6–2.2 FOXG1 patients per 100,000 children or ~ 430–1600 patients in the United States. The estimated prevalence of CDLK5 patients was 2.1–7.7 cases per 100,000 female children, and the estimated prevalence of MECP2 patients was 3.2–11.9 cases per 100,000 female children. Conclusions Estimated prevalence of MECP2-driven severe NDD was comparable to estimates based on Rett Syndrome clinical criteria. Similarly, CDKL5-driven NDD were also comparable to an earlier study. However, prevalence estimates for FOXG1-associated severe NDD were ~ 10 times higher than expected if limited to reports based on Rett Syndrome clinical criteria. This data further supports that both FOXG1 Syndrome and CDKL5 deficiency represent distinct and sizable patient populations as compared to MECP2-associated Rett Syndrome. These findings have immediate implications for improved diagnosis of these patients and highlight the benefits of genetic testing in identifying them.
- 2 September 2024
- Published by Springer Nature in Research Square
Open AccessThe emerging face of FOXG1 Syndrome: a rare, genetically defined neurodevelopmental disorder coming of age in the genomics era.
Background and Objectives FOXG1 Syndrome was first identified in 2005 and has been closely associated with Rett Syndrome. However, with access to genetic testing an increasing number of patients have been identified that do not fulfill Rett Syndrome clinical criteria. Utilizing genetic surveys of large, severe neurodevelopmental disease (NDD) cohorts, we provide the first prevalence estimates of FOXG1 Syndrome independent of Rett Syndrome clinical criteria. Methods We performed a systematic review and meta-analysis of studies conducting extensive genetic testing on cohorts of severe neurodevelopmental patients within the last ten years. Fourteen studies were included, after exclusion of outliers biased for FOXG1 patients, providing analysis of over 36,000 severe neurodevelopmental disease pediatric patients in total. Results FOXG1 patients accounted for 0.20% [95% CI: 0.15–0.25%] of severe NDD pediatric patients. MECP2 and CDKL5 patients accounted for 0.54% [95% CI: 0.47–0.62%] and 0.35% [95% CI: 0.29–0.41%], respectively. This results in an estimated prevalence of 0.6–2.2 FOXG1 patients per 100,000 children or ~ 430–1600 patients in the United States. The estimated prevalence of CDLK5 patients was 2.1–7.7 cases per 100,000 female children, and the estimated prevalence of MECP2 patients was 3.2–11.9 cases per 100,000 female children. Conclusions Estimated prevalence of MECP2-driven severe NDD was comparable to estimates based on Rett Syndrome clinical criteria. Similarly, CDKL5-driven NDD were also comparable to an earlier study. However, prevalence estimates for FOXG1-associated severe NDD were ~ 10 times higher than expected if limited to reports based on Rett Syndrome clinical criteria. This data further supports that both FOXG1 Syndrome and CDKL5 deficiency represent distinct and sizable patient populations as compared to MECP2-associated Rett Syndrome. These findings have immediate implications for improved diagnosis of these patients and highlight the benefits of genetic testing in identifying them.
- Open Access
- 6 July 2021
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 16 (1) , 1-8
Genetic epidemiology approach to estimating birth incidence and current disease prevalence for rhizomelic chondrodysplasia punctata
Background: Rhizomelic chondrodysplasia punctata (RCDP) is an inherited ultra-rare disease which results in severely impaired physical and mental development. Mutations in one of five genes involved in plasmalogen biosynthesis have been reported to drive disease pathology. Estimates of disease incidence have been extremely challenging due to the rarity of the disorder, preventing an understanding of the unmet medical need. To address this, we have prepared a disease incidence and prevalence model based on genetic epidemiology approaches to estimate the total number of RCDP patients affected, and their demographic characteristics. Results: Extraction of allelic frequencies for known and predicted pathogenic variants in PEX7, GNPAT, AGPS, FAR1, PEX5 (limited to the PTS2 domain encoding region) genes, from large-scale human genetic diversity datasets (TopMed and gnomAD) revealed the mutational landscape contributing to the RCDP patient population in the US and Europe. We computed genetic prevalence to derive birth incidence for RCDP and modeled the impact to life expectancy to obtain high confidence estimates of disease prevalence. Our population genetics-based model indicates PEX7 variants are expected to contribute to the majority of RCDP cases in both the US and Europe; closely aligning with clinical reports. Furthermore, this model provides estimates for RCDP subtypes due to mutations in other genes, including exceedingly rare subtypes. Conclusion: In total, the estimated number of RCDP patients in the US and the five largest European countries (UK, Germany, France, Italy and Spain) is between 516 and 847 patients, all under the age of 35 years old. This model provides a quantitative framework for better understanding the unmet medical need in RCDP, to help guide disease awareness and diagnosis efforts for this specific patient group.
- 6 July 2021
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 16 (1) , 1-8
Open AccessGenetic epidemiology approach to estimating birth incidence and current disease prevalence for rhizomelic chondrodysplasia punctata
Background: Rhizomelic chondrodysplasia punctata (RCDP) is an inherited ultra-rare disease which results in severely impaired physical and mental development. Mutations in one of five genes involved in plasmalogen biosynthesis have been reported to drive disease pathology. Estimates of disease incidence have been extremely challenging due to the rarity of the disorder, preventing an understanding of the unmet medical need. To address this, we have prepared a disease incidence and prevalence model based on genetic epidemiology approaches to estimate the total number of RCDP patients affected, and their demographic characteristics. Results: Extraction of allelic frequencies for known and predicted pathogenic variants in PEX7, GNPAT, AGPS, FAR1, PEX5 (limited to the PTS2 domain encoding region) genes, from large-scale human genetic diversity datasets (TopMed and gnomAD) revealed the mutational landscape contributing to the RCDP patient population in the US and Europe. We computed genetic prevalence to derive birth incidence for RCDP and modeled the impact to life expectancy to obtain high confidence estimates of disease prevalence. Our population genetics-based model indicates PEX7 variants are expected to contribute to the majority of RCDP cases in both the US and Europe; closely aligning with clinical reports. Furthermore, this model provides estimates for RCDP subtypes due to mutations in other genes, including exceedingly rare subtypes. Conclusion: In total, the estimated number of RCDP patients in the US and the five largest European countries (UK, Germany, France, Italy and Spain) is between 516 and 847 patients, all under the age of 35 years old. This model provides a quantitative framework for better understanding the unmet medical need in RCDP, to help guide disease awareness and diagnosis efforts for this specific patient group.